Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ecopipam

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Acquires Emalex, Adding NDA-Ready Therapy
    Teva Acquires Emalex, Adding NDA-Ready Therapy

    29 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/29/3283566/0/en/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-teva-s-pivot-to-growth-strategy.html

    GLOBENEWSWIRE
    29 Apr 2026
    Share Share
    Emalex Wins US Patent for Oral Ecopipam Formulation
    Emalex Wins US Patent for Oral Ecopipam Formulation

    09 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260407152501/en/Emalex-Receives-U.S.-Patent-for-Orally-Disintegrating-Ecopipam-Formulation

    BUSINESSWIRE
    09 Apr 2026
    Share Share
    First Patient Dosed In Emalex Biosciences' Expanded Access
    First Patient Dosed In Emalex Biosciences' Expanded Access

    09 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260309694968/en/First-Patient-Dosed-in-Emalex-Biosciences-Expanded-Access-Program-for-Investigational-Tourette-Syndrome-Therapy

    BUSSINESSWIRE
    09 Mar 2026
    Share Share
    Emalex’s Lead Drug Hits Goals In Ph 3 Tourette Study
    Emalex’s Lead Drug Hits Goals In Ph 3 Tourette Study

    25 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250225561932/en

    BUSINESSWIRE
    25 Feb 2025
    Share Share
    Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam
    Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam

    01 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/emalex-biosciences-announces-first-patient-dosed-in-phase-3-trial-of-ecopipam-for-tourette-syndrome-301759554.html

    PR NEWSWIRE
    01 Mar 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.